• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders.

作者信息

Kaminski Hannah, Gigan Mickael, Vermorel Agathe, Charrier Manon, Guirle Laura, Jambon Frederic, Lacapère Arthur, Ménard Coline, Moreau Karine, Neau-Cransac Martine, Novion Marine, Pribat Frederique, Taton Benjamin, Borde Sébastien, Burguet Laure, Martinez Charlie, Jasiek Magali, D'Halluin Pauline, Lafon Marie-Edith, Merville Pierre, Couzi Lionel

机构信息

Department of Nephrology, Transplantation, Dialysis and Apheresis, Bordeaux University Hospital, Bordeaux, France.

Department of Pharmacy, Bordeaux University Hospital, Bordeaux, France.

出版信息

Kidney Int. 2022 Oct;102(4):936-938. doi: 10.1016/j.kint.2022.07.008. Epub 2022 Jul 20.

DOI:10.1016/j.kint.2022.07.008
PMID:35870641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9297679/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5734/9297679/6a1ac823d17c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5734/9297679/6a1ac823d17c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5734/9297679/6a1ac823d17c/gr1_lrg.jpg

相似文献

1
COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders.在肾移植受者无应答者或低疫苗应答者中，替沙格韦单抗-西加韦单抗暴露前预防可降低COVID-19发病率。
Kidney Int. 2022 Oct;102(4):936-938. doi: 10.1016/j.kint.2022.07.008. Epub 2022 Jul 20.
2
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
3
Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.替沙格韦单抗-西加韦单抗作为新型冠状病毒肺炎暴露前预防的疗效和安全性：一项系统评价和荟萃分析
Rev Med Virol. 2023 Mar;33(2):e2420. doi: 10.1002/rmv.2420. Epub 2023 Jan 8.
4
Risk factors for breakthrough COVID-19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre-exposure prophylaxis.接受替沙格韦单抗/西加韦单抗进行暴露前预防的实体器官移植受者中出现COVID-19突破性感染的风险因素。
Transpl Infect Dis. 2023 Dec;25(6):e14125. doi: 10.1111/tid.14125. Epub 2023 Aug 18.
5
[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].[替沙格韦单抗/西加韦单抗对莫斯科原发性免疫缺陷成年患者进行新型冠状病毒肺炎暴露前预防]
Ter Arkh. 2023 Feb 24;95(1):78-84. doi: 10.26442/00403660.2023.01.202088.
6
Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.泰它西单抗-西加韦单抗：COVID-19 暴露前预防。
Clin J Oncol Nurs. 2022 Sep 15;26(5):479-482. doi: 10.1188/22.CJON.479-482.
7
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.替沙格韦单抗/西加韦单抗用于 COVID-19 的预防和治疗：综述。
Expert Rev Anti Infect Ther. 2022 Dec;20(12):1517-1527. doi: 10.1080/14787210.2022.2134118. Epub 2022 Oct 27.
8
Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.在日本的一家机构中，针对奥密克戎 BA.5 波进行的 2019 年冠状病毒病（COVID-19）用替沙格韦单抗/西加韦单抗的预先暴露预防。
Int J Hematol. 2023 Dec;118(6):731-736. doi: 10.1007/s12185-023-03663-2. Epub 2023 Sep 25.
9
Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19: A case series.肝移植受者在接受 tixagevimab/cilgavimab 进行 COVID-19 暴露前预防后出现肌痛：病例系列研究。
Transpl Infect Dis. 2022 Dec;24(6):e13932. doi: 10.1111/tid.13932. Epub 2022 Aug 23.
10
[Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19].替沙格韦单抗和西加韦单抗联合用于新型冠状病毒肺炎暴露前预防的药物经济学评价
Ter Arkh. 2023 Feb 24;95(1):66-77. doi: 10.26442/00403660.2023.01.202065.

引用本文的文献

1
Clinical outcomes in kidney transplant recipients receiving tixagevimab/cilgavimab for outpatient treatment of COVID-19: a single-center retrospective study.接受替沙格韦单抗/西加韦单抗门诊治疗新冠肺炎的肾移植受者的临床结局：一项单中心回顾性研究
Front Transplant. 2025 Jun 10;4:1579226. doi: 10.3389/frtra.2025.1579226. eCollection 2025.
2
Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19.揭示保护作用：对28950名移植受者和免疫功能低下患者使用替沙格韦单抗-西加韦单抗预防COVID-19的荟萃分析
Virol J. 2025 Jun 2;22(1):178. doi: 10.1186/s12985-025-02814-7.
3
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.
奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
4
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种的中和单克隆抗体（nMAbs）的治疗潜力
Curr Pharm Des. 2025;31(10):753-773. doi: 10.2174/0113816128334441241108050528.
5
Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study.替沙格韦单抗-西加韦单抗预防透析患者新冠病毒突破性感染的前瞻性研究
Clin Kidney J. 2024 Oct 18;17(11):sfae309. doi: 10.1093/ckj/sfae309. eCollection 2024 Nov.
6
Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.替沙格韦单抗/西加韦单抗预防实体器官移植受者感染新型冠状病毒肺炎的系统评价与Meta分析
Clin Transplant Res. 2024 Jun 30;38(2):136-144. doi: 10.4285/ctr.24.0015. Epub 2024 Jun 21.
7
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.mRNA 疫苗接种后肾移植受者对 SARS-CoV-2 奥密克戎亚变种的中和抗体反应和细胞反应。
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
8
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.替沙格韦单抗/西加韦单抗用于肾移植受者暴露前预防的安全性和有效性：一项多中心回顾性队列研究。
J Nephrol. 2024 Jul;37(6):1539-1550. doi: 10.1007/s40620-024-01889-9. Epub 2024 May 23.
9
Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose.接受单克隆抗体预防的肾移植受者对SARS-CoV-2的T细胞反应评估及二价mRNA疫苗加强剂量的效用
Microorganisms. 2024 Apr 2;12(4):722. doi: 10.3390/microorganisms12040722.
10
The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients.mRNA BNT162b第三剂疫苗在实体器官移植受者中的长期免疫原性
Vaccines (Basel). 2024 Feb 22;12(3):224. doi: 10.3390/vaccines12030224.